Andres Y. Maldonado
Stock Analyst at HC Wainwright & Co.
(2.30)
# 2,663
Out of 4,974 analysts
5
Total ratings
75%
Success rate
5.26%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andres Y. Maldonado
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGON CG Oncology | Reiterates: Buy | $75 | $33.07 | +126.79% | 1 | Sep 5, 2025 | |
| MNPR Monopar Therapeutics | Assumes: Buy | $70 | $44.21 | +58.34% | 1 | Aug 26, 2025 | |
| IMAB I-Mab | Reiterates: Buy | $7 | $4.38 | +59.82% | 1 | Aug 21, 2025 | |
| AURA Aura Biosciences | Reiterates: Buy | $22 | $6.46 | +240.56% | 1 | Aug 13, 2025 | |
| KROS Keros Therapeutics | Maintains: Buy | $25 → $20 | $15.55 | +28.62% | 1 | Aug 8, 2025 |
CG Oncology
Sep 5, 2025
Reiterates: Buy
Price Target: $75
Current: $33.07
Upside: +126.79%
Monopar Therapeutics
Aug 26, 2025
Assumes: Buy
Price Target: $70
Current: $44.21
Upside: +58.34%
I-Mab
Aug 21, 2025
Reiterates: Buy
Price Target: $7
Current: $4.38
Upside: +59.82%
Aura Biosciences
Aug 13, 2025
Reiterates: Buy
Price Target: $22
Current: $6.46
Upside: +240.56%
Keros Therapeutics
Aug 8, 2025
Maintains: Buy
Price Target: $25 → $20
Current: $15.55
Upside: +28.62%